• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Upexi Inc.

    9/30/24 4:09:25 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $UPXI alert in real time by email
    NT 10-K 1 upxi_nt10k.htm NT 10-K upxi_nt10k.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON D.C. 20549

     

    FORM 12b-25

    NOTIFICATION OF LATE FILING

     

    (Check One):

    ☒ Form 10-K     ☐ Form 20-F     ☐ Form 11-K     ☐ Form 10-Q     ☐ Form N-SAR

     

    For Period Ended: June 30, 2024

     

    ☐

    Transition Report on Form 10-K

    ☐

    Transition Report on Form 20-F

    ☐

    Transition Report on Form 11-K

    ☐

    Transition Report on Form 10-Q

    ☐

    Transition Report on Form N-SAR

     

    For the Transition Period Ended: _________

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    PART I - REGISTRANT INFORMATION

     

     

    Upexi, Inc.

     

     

    Full Name of Registrant

     

     

     

     

     

     

    Former Name if Applicable

     

     

     

    3030 N. Rocky Point Drive, Suite 420

     

     

    Address of Principal Executive Office (Street and Number)

     

     

     

     

     

    Tampa, FL 33607

     

     

    City, State, Zip Code

     

     

     

     

       

    PART II - RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

     

    (a)

    The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

    ☒

    (b)

    The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

     

    (c)

    The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III - NARRATIVE

     

    State below in reasonable detail the reasons why the Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof could not be filed within the prescribed time period. (Attach extra sheets if needed)

     

    Upexi, Inc. (the “Company”) is unable to file its Annual Report on Form 10-K for the year ended June 30, 2024 (the “Form 10-K”) on or prior to September 30, 2024 without unreasonable effort and expense. The Form 10-K can not be filed within the prescribed time because additional time is required by Registrant’s management and auditors to prepare certain financial information to be included in such report.

     

    PART IV - OTHER INFORMATION

     

    (1)

    Name and telephone number of person to contact in regard to this notification:

     

     

    Andrew Norstrud

     

    (701)

     

    353-5425

     

    (Name)

     

    Area Code

     

    (Telephone No.)

     

    (2)

    Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).  ☒ Yes   ☐ No

     

    (3)

    Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?  ☐ Yes    ☒ No

     

     

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

    2

     

     

     

    Upexi, Inc.

     

     

    (Name of Registrant as Specified in Charter)

     

     

    has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

     

    Date: September 30, 2024

    By:

    /s/ Andrew Norstrud

     

     

    Name:

    Andrew Norstrud,

     

     

    Title:

    Chief Financial Officer

     

     

     

    3

     

    Get the next $UPXI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UPXI

    DatePrice TargetRatingAnalyst
    8/4/2025$15.00Buy
    Alliance Global Partners
    6/16/2025$16.00Neutral → Overweight
    Cantor Fitzgerald
    More analyst ratings

    $UPXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Marshall Allan bought $90,000 worth of shares (50,000 units at $1.80), increasing direct ownership by 1% to 4,046,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/23/25 7:53:48 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan was granted 1,600,000 shares and bought $310,500 worth of shares (150,000 units at $2.07), increasing direct ownership by 78% to 3,996,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/17/25 6:43:21 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Salkind Gene bought $127,500 worth of shares (50,000 units at $2.55) (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    11/21/25 6:32:50 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Upexi Announces Pricing of $7.4 Million Registered Direct Offering With a Single Institutional Investor

    TAMPA, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it has entered into a definitive agreement with a single institutional investor for the sale and issuance of 6,337,000 shares of common stock of the Company and warrants to purchase up to 6,337,000 shares of common stock at a combined offering price of $1.17 per share of common stock and accompanying warrant, in a registered direct offering. The warrants have an exercise price of $1.50 per share, will be exercisable immediately upon issuance, and will expire five (5) years following the d

    2/6/26 8:33:38 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Host Second Quarter 2026 Earnings Call on February 10th at 5:30 p.m. ET

    TAMPA, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it plans to host a conference call and report its financial results for the second quarter 2026 ended December 31, 2025, on Tuesday, February 10, 2026. Additional details are available under the Investor Relations section of the Company's website: https://ir.upexi.com/ Event:Upexi Second Quarter 2026 Earnings CallDate:Tuesday, February 10, 2026Time:5:30 p.m. ETLive Call:1-877-407-9716 (U.S. Toll-Free) or 1-201-493-6779 (International)Webcasthttps://ir.upexi.com/news-events/ir-calendar For

    1/29/26 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Announces Pricing of $36 Million Private Placement of Convertible Note Priced Above the Market

    Transaction to Increase Solana Treasury by 12% to over 2.4 million SOL Offering is Accretive to Adjusted Solana per Share upon Conversion TAMPA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it has entered into a securities purchase agreement with Hivemind Capital Partners for the purchase of a Convertible Note in exchange for locked Solana with an aggregate original principal amount of approximately $36 million (the "Note"). The Note is collateralized by the SOL used as consideration to purchase the Note. It has an interest rate of 1.0% payable on a quarterly basi

    1/13/26 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    SEC Filings

    View All

    SEC Form 424B7 filed by Upexi Inc.

    424B7 - UPEXI, INC. (0001775194) (Filer)

    2/4/26 5:26:14 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B5 filed by Upexi Inc.

    424B5 - UPEXI, INC. (0001775194) (Filer)

    2/4/26 5:24:48 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    2/4/26 5:23:53 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Marshall Allan bought $90,000 worth of shares (50,000 units at $1.80), increasing direct ownership by 1% to 4,046,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/23/25 7:53:48 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan was granted 1,600,000 shares and bought $310,500 worth of shares (150,000 units at $2.07), increasing direct ownership by 78% to 3,996,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/17/25 6:43:21 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Salkind Gene bought $127,500 worth of shares (50,000 units at $2.55) (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    11/21/25 6:32:50 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Upexi, Inc. with a new price target

    Alliance Global Partners initiated coverage of Upexi, Inc. with a rating of Buy and set a new price target of $15.00

    8/4/25 8:09:26 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi, Inc. upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Upexi, Inc. from Neutral to Overweight and set a new price target of $16.00

    6/16/25 7:42:40 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Leadership Updates

    Live Leadership Updates

    View All

    Upexi Welcomes Jon Najarian to the Upexi Advisory Committee

    TAMPA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced the addition of Jon Najarian (Twitter: @jonnajarian) to the Upexi Advisory Committee, joining Arthur Hayes and S◎L Big Brain as founding Upexi Advisory Committee members. Jon Najarian is a highly influential figure in the world of finance, renowned for his deep expertise in options trading and market strategy. A former professional football player, Jon co-founded options trading firm Mercury Trading and later launched financial education company Marke

    10/23/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Establishes Advisory Committee and Welcomes Arthur Hayes as First Member

    Additional members to join the Advisory Committee in the coming weeks to optimize performance, increase visibility and unlock capital raising opportunities Arthur brings deep expertise, exposure and connectivity to both digital assets and traditional finance TAMPA, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the establishment of the Upexi Advisory Committee, composed of highly prominent individuals from the digital assets and traditional finance industries. Upexi will seek t

    8/12/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Financials

    Live finance-specific insights

    View All

    Upexi to Host Second Quarter 2026 Earnings Call on February 10th at 5:30 p.m. ET

    TAMPA, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it plans to host a conference call and report its financial results for the second quarter 2026 ended December 31, 2025, on Tuesday, February 10, 2026. Additional details are available under the Investor Relations section of the Company's website: https://ir.upexi.com/ Event:Upexi Second Quarter 2026 Earnings CallDate:Tuesday, February 10, 2026Time:5:30 p.m. ETLive Call:1-877-407-9716 (U.S. Toll-Free) or 1-201-493-6779 (International)Webcasthttps://ir.upexi.com/news-events/ir-calendar For

    1/29/26 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Reports Record Digital Asset Revenue for Fiscal First Quarter 2026

    Digital Asset Revenue was Approximately $6.1 Million for the Quarter Gross Profit Totaled $8.3 Million, up 183% Year-Over-Year Net Income Increased to $66.7 Million, Compared to a Net Loss of $1.6 Million, Year-over-Year Conference Call Scheduled for today, November 11, 2025, at 5:30 p.m. Eastern Time TAMPA, Fla., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) ("Upexi" or the "Company"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced record digital asset revenue for the fiscal first quarter ended September 30, 2025. Financial Highlights for the Quarter Ended September 30, 2025 Total revenue for the quarter was $9.2 mill

    11/11/25 5:25:00 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Host First Quarter 2026 Earnings Call on November 11th at 5:30 p.m. ET

    TAMPA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it plans to host a conference call and report its financial results for the first quarter 2026 ended September 30, 2025, on Tuesday, November 11, 2025. Additional details are available under the Investor Relations section of the Company's website: https://ir.upexi.com/ Event:Upexi First Quarter 2026 Earnings CallDate:Tuesday, November 11, 2025Time:5:30 p.m. ETLive Call:1-877-407-9716 (U.S. Toll-Free) or 1-201-493-6779 (International)Webcasthttps://ir.upexi.com/news-events/ir-calendar Fo

    11/6/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    5/31/23 7:05:10 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:37:37 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

    SC 13G/A - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:36:56 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care